InMed Pharmaceuticals (FRA:MWG) Change In Receivables: €0.24 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MWG InMed Pharmaceuticals Inc FRA:MWG
32 GF Score
Price €1.18
GF Value €0.75
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Change In Receivables?

InMed Pharmaceuticals FRA:MWG 32 Change In Receivables is €0.24 Mil as of Mar. 2026. GuruFocus rates FRA:MWG with a GF Score™ of 32/100 and a GF Value™ of €0.75 (Significantly Overvalued). The stock has 2 warning signs investors should review.

InMed Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2026 was €0.00 Mil. It means InMed Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

InMed Pharmaceuticals's change in receivables for the fiscal year that ended in Jun. 2025 was €-0.10 Mil. It means InMed Pharmaceuticals's Accounts Receivable increased by €0.10 Mil from Jun. 2024 to Jun. 2025 .

InMed Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. InMed Pharmaceuticals's liquidation value for the three months ended in Mar. 2026 was €2.52 Mil.

InMed Pharmaceuticals  (FRA:MWG) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

InMed Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, InMed Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

InMed Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=4.463-1.939+0.75 * 0+0.5 * 0
=2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals Change In Receivables Related Terms

InMed Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals Change In Receivables Chart

InMed Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -0.04 -0.20 -0.09 -0.10

InMed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.10 0.14 0.00
FRA:MWG
32GF Score
InMed Pharmaceuticals Inc FRA:MWG
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InMed Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €0.24 Mil mean?
InMed Pharmaceuticals (FRA:MWG) has a Change In Receivables of €0.24 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for InMed Pharmaceuticals and its competitors.
Is InMed Pharmaceuticals' Change In Receivables too high?
InMed Pharmaceuticals' current Change In Receivables is €0.24 Mil. Overall, InMed Pharmaceuticals has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Change In Receivables compare to APUS and GELS?
InMed Pharmaceuticals' Change In Receivables of €0.24 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current Change In Receivables is €0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (FRA:MWG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.75, compared to a current price of €1.18 — trading 57.3% above its estimated fair value. The current Change In Receivables is €0.24 Mil. InMed Pharmaceuticals' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For InMed Pharmaceuticals (FRA:MWG), the current Change In Receivables is €0.24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InMed Pharmaceuticals (FRA:MWG) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of €1.18 is trading 57.3% above its estimated GF Value™ of €0.75. GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:MWG:

  • Change In Receivables: €0.24 Mil
  • GF Value™: €0.75 vs. price of €1.18 (57.3% above fair value)
  • GF Score™: 32/100 with 2 warning signs

No single metric tells the full story. See the FRA:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InMed Pharmaceuticals Business Description

Other Exchanges INM:USA
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
32GF Score

Get the complete analysis for FRA:MWG

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.18
Price
€0.75
GF Value